Non-vitamin K antagonist oral anticoagulants (NOACs) have changed the landscape for
stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, more …

Research into new anticoagulants for preventing and treating thromboembolic disorders has
focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and …

Background Severe traumatic injury continues to present challenges to healthcare systems
around the world, and post-traumatic bleeding remains a leading cause of potentially …

Background Severe trauma continues to represent a global public health issue and mortality
and morbidity in trauma patients remains substantial. A number of initiatives have aimed to …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …

Apixaban does not require monitoring nor frequent dose adjustment. However, searching for
the optimal dose for the individual patient may be useful in some situations. Moreover, there …

Aim To compare the efficacy and safety of edoxaban and warfarin for treatment of portal vein
thrombosis (PVT) following danaparoid sodium in patients with liver cirrhosis. Methods Fifty …

New oral anticoagulants (NOAC) are becoming available as alternatives to warfarin to
prevent systemic embolism in patients with non‐valvular atrial fibrillation and for the …

Possibilities to monitor rivaroxaban therapy could be useful in certain circumstances.
Prothrombin time (PT) or chromogenic anti-Xa assays such as the Biophen Direct Factor Xa …

Owing to the propensity of anticoagulated patients to bleed, a strategy for reversal of
anticoagulation induced by any of the common agents is essential. Many patients are …